Genetically modified non-human animal with human or chimeric CD27
The present disclosure relates to genetically modified non-human animals (e.g., genetically-modified mice) that express a human or chimeric (e.g., humanized) CD27. The present disclosure also relates to methods of generating the genetically-modified animals (e.g., genetically modified mice), and methods of using the genetically modified non-human animals (e.g., genetically modified mice) described herein.
1. A genetically-modified mouse whose genome comprises at least one chromosome comprising a nucleic acid sequence encoding a human or chimeric CD27, wherein the mouse expresses the human or chimeric CD27 on the surface of one or more spleen cells after the genetically modified mouse is stimulated by anti-CD3 antibody, and the mouse does not express endogenous CD27.
2. The mouse of claim 1 , wherein the nucleic acid sequence encoding the human or chimeric CD27 is operably linked to an endogenous regulatory element at the endogenous CD27 gene locus in the at least one chromosome.
3. The mouse of claim 1 , wherein the nucleic acid sequence encodes an amino acid sequence that is at least 70% identical to SEQ ID NO: 18.
4. The mouse of claim 1 , wherein the nucleic acid sequence encodes an amino acid sequence that is at least 70% identical to SEQ ID NO: 24.
5. The mouse of claim 1 , wherein the nucleic acid sequence encodes a human or chimeric CD27 comprising amino acids 1-183 of SEQ ID NO: 18.
6. The mouse of claim 1 , wherein the genome of the mouse comprises a replacement of a sequence encoding a region of endogenous CD27 with a sequence encoding a corresponding region of human CD27 at an endogenous CD27 gene locus.
7. The mouse of claim 6 , wherein the region of the endogenous CD27 is the extracellular region of CD27.
8. The mouse of claim 6 , wherein the mouse has one or more spleen cells expressing a chimeric CD27 having an extracellular region, a transmembrane region, and a cytoplasmic region, wherein the extracellular region comprises a sequence that is at least 80% identical to the extracellular region of human CD27.
9. The mouse of claim 6 , wherein the mouse is homozygous with respect to the replacement at the endogenous CD27 gene locus.
10. The mouse of claim 1 , wherein the nucleic acid sequence encodes an amino acid sequence that is at least 90% identical to SEQ ID NO: 24.
11. The mouse of claim 1 , wherein the nucleic acid sequence encodes an amino acid sequence that is at least 95% identical to SEQ ID NO: 24.
12. The mouse of claim 1 , wherein the nucleic acid sequence encodes an amino acid sequence comprising SEQ ID NO: 24.